Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

NCT06462729 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to evaluate the safety and effectiveness of LDGraft (investigational device) compared to 100% human tissue product allograft bone (control) when applied in an ALIF procedure in the treatment of patients with lumbar degenerative disc disease (DDD).

Interventions

  • DEVICE LDGraft
  • OTHER Allograft Bone

Study Locations (3)

New South Wales

  • Newcastle Private Hospital — Newcastle
  • Macquarie University — Sydney

Indiana

  • Orthopaedics NorthEast — Fort Wayne

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-11-12
Est. Completion 2027-12
Phase Phase 1

Sponsor

Locate Bio Pty

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06462729

The ClinicalTrials.gov registry entry for NCT06462729 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Locate Bio Pty, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Degenerative Disc Disease appearing as the primary indexed condition, and to 2 interventions — of which LDGraft is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06462729 reports 3 study locations spanning 2 distinct geographic areas — top geographies include New South Wales, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06462729 about?

NCT06462729 is a clinical study titled "LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)". The objective of this study is to evaluate the safety and effectiveness of LDGraft (investigational device) compared to 100% human tissue product allograft bone (control) when applied in an ALIF procedure in the treatment of patients with lumbar degenerative disc disease (DDD).

What is the current status of trial NCT06462729?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-11-12. Estimated completion is 2027-12.

What conditions does trial NCT06462729 study?

This clinical trial studies the following conditions: Degenerative Disc Disease, Lumbar Spine Degeneration, Spine Disease, Lumbar Disc Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06462729?

The interventions under investigation include: LDGraft (DEVICE), Allograft Bone (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06462729?

This trial is sponsored by Locate Bio Pty, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06462729 being conducted?

This trial has 3 study locations across Indiana, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial